Background and development
Semaglutide is a 31-amino-acid synthetic peptide developed by Novo Nordisk, with 94% structural homology to native human GLP-1. It is one of the most extensively studied incretin-based therapies, available as injectable and oral formulations across multiple approved indications (type 2 diabetes, chronic weight management) and dose ranges.
Mechanism of action
Semaglutide is a selective GLP-1 receptor agonist. The drug:
- Stimulates glucose-dependent insulin secretion from pancreatic beta cells
- Suppresses glucagon secretion (lowering hepatic glucose output)
- Slows gastric emptying, prolonging satiety after meals
- Acts in the central nervous system to reduce appetite and food intake
Plasma half-life is approximately 7 days, supporting once-weekly subcutaneous administration. Steady-state is reached after 4 to 5 weeks of consistent dosing.
FDA-approved formulations and dosing
This is a prescription medication. Dosing is established by your prescriber based on indication, response, and tolerability.
Ozempic, weekly injection for T2D
0.25 mg weekly for 4 weeks (titration), then 0.5 mg weekly. May escalate to 1 mg or 2 mg at 4-week intervals based on glycemic response.
Wegovy, weekly injection for weight management
0.25 mg weekly for 4 weeks, escalating in 0.25–0.5 mg steps every 4 weeks to a 2.4 mg maintenance dose. Wegovy HD adds escalation to a 7.2 mg dose.
Rybelsus, daily oral tablet for T2D
3 mg daily for 30 days, then 7 mg, with optional escalation to 14 mg. Must be taken on an empty stomach with no more than 4 oz water, at least 30 minutes before any food, beverage, or other oral medication.
Oral Wegovy, daily oral tablet for weight management
Maintenance 25 mg daily after dose escalation. Same empty-stomach administration requirements as Rybelsus.
The SUSTAIN, STEP, and SELECT programs
SUSTAIN, type 2 diabetes
10 randomized controlled trials evaluating semaglutide in T2D across diverse patient populations. Across the program, semaglutide produced consistent A1C reductions and cardiovascular outcome benefits in defined subgroups.
STEP, chronic weight management
The Phase 3 program for the weight-management indication. Selected results:
- STEP-1: ~14.9% mean weight loss at 2.4 mg weekly over 68 weeks in adults with overweight or obesity but without T2D.
- STEP-2: ~9.6% mean weight loss in adults with both T2D and obesity.
- STEP-3: ~16.0% with intensive behavioral therapy in addition to semaglutide.
- STEP-1 extension: participants who stopped regained ~two-thirds of weight loss over the year following discontinuation.
- STEP UP: ~20.7% mean weight loss at 7.2 mg dose, supporting the Wegovy HD approval.
SELECT, cardiovascular outcomes
17,604 adults with overweight or obesity and pre-existing cardiovascular disease, no diabetes. Semaglutide 2.4 mg weekly reduced major adverse cardiovascular events (cardiovascular death, nonfatal MI, nonfatal stroke) by 20% compared with placebo, over a mean follow-up of 39.8 months.
OASIS, oral semaglutide for weight management
Phase 3 trials supporting the oral Wegovy approval. OASIS-4 reported ~16.6% mean weight loss at 25 mg daily over 64 weeks.
Side effects and safety profile
The most common adverse events are gastrointestinal: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite. Most are mild-to-moderate, dose-dependent, and improve with continued dosing.
Approximately 4–6% of trial participants discontinued semaglutide due to adverse events.
Boxed warning: thyroid C-cell tumors observed in rodent studies. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2.
Additional warnings: pancreatitis, severe GI disease, gallbladder disease, hypoglycemia (especially with insulin or sulfonylureas), acute kidney injury, hypersensitivity, retinopathy progression in T2D, and post-marketing reports related to suicidal thoughts under FDA review.
References
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). "Once-weekly semaglutide in adults with overweight or obesity (STEP-1)." N Engl J Med, 384(11), 989–1002. PubMed
- Garvey WT, Frias JP, Jastreboff AM, et al. (2025). "Semaglutide 7.2 mg in adults with overweight or obesity (STEP UP)." The Lancet. PubMed
- Sorli C, Harashima SI, Tsoukas GM, et al. (2017–2019). "SUSTAIN-1 through SUSTAIN-10 trials." Various journals. PubMed
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). "Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT)." N Engl J Med, 389(24), 2221–2232. PubMed
- Knop FK, Aroda VR, do Vale RD, et al. (2023). "Oral semaglutide 25 mg taken once daily in adults with overweight or obesity (OASIS-4)." The Lancet. PubMed
- Wilding JPH, Batterham RL, Davies M, et al. (2022). "Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP-1 trial extension." Diabetes Obes Metab, 24(8), 1553–1564. PubMed
- U.S. Food and Drug Administration. "Ozempic Prescribing Information." FDA.gov
- U.S. Food and Drug Administration. "Wegovy Prescribing Information." FDA.gov